ORIGINAL ARTICLE

Survival in stomach cancer: analysis of a national cancer information system and a population-based cancer registry in Colombia

Supervivencia del cáncer de estómago: análisis de un sistema de información nacional sobre el cáncer y de un registro de cáncer de base poblacional en Colombia

Luis Eduardo Bravo,[1,2] (iD) Juliana Alexandra Hernández Vargas,[3] (iD) Paola Collazos,[2] (iD) Luz Stella García,[2] (iD) Ana María Valbuena,[3] (iD) Lizbeth Acuña[3] (iD)
jhernandez@cuentadealtocosto.org

1 Registro Poblacional de Cáncer de Cali, Cali, Colombia. 2 Universidad del Valle, Facultad de Salud, Escuela de Medicina, Departamento de Patología, Cali, Colombia. , 3 Cuenta de Alto Costo, Fondo Colombiano de Enfermedades de Alto Costo, Bogotá, Colombia.

Abstract

Background:

Stomach cancer is among the most frequent, is a leading cause of mortality in low- and middle-income countries. Assessing its survival is important to guide evidence-based health policies.

Aims:

To estimate stomach cancer survival in Colombia (2014-2019) with data from the National Cancer Information System (NCIS) and in Cali with data from the Cali Population Cancer Registry (RPCC) (1998-2017).

Methods:

NCIS estimated the overall 3-year net survival for 8,549 people, while RPCC estimated 5-year net survival for 6,776 people.

Results:

The 3-year net survival was 36.8% (95% CI: 35.5-38.1). Net survival was higher in people with special insurance (61.7%; 95% CI: 44.8-74.8) or third payer (40.5%; 95% CI: 38.7-42.3) than state insurance (30.7%; 95% CI: 28.7-32.8). It was also higher in women and people diagnosed at early stages. Multivariable analysis showed consistency with survival estimations with a higher risk of death in men, people with state insurance, and diagnosed at advanced stages. In Cali, the 5-year net survival remained stable in men during the last 20 years. In women the 5-year net survival in women increased 8.60 percentage points, equivalent to a 50% increase compared to the 1998-2002 period. For 2013-17, it was 19.1% (95%CI: 16.2-22.2) in men, and 24.8% (95% CI: 20.4-29.3) in women.

Conclusions:

Population survival estimates from the RPCC were lower than those observed in the NCIS. The differences in their methods and scope can explain variability. Nevertheless, our findings could be complementary to improve cancer control planning in the country.

Conflicts of interest:

The authors declare that they have no conflict of interest.

Corresponding author:

Juliana Alexandra Hernández Vargas. Cuenta de Alto Costo, Fondo Colombiano de Enfermedades de Alto Costo. Address: Avenue career 45 number 103-34, Building Logic 2, Office 802, Bogotá, Colombia. Postal code: 110111. Phone: (57) 1 6021820. **E-mail:** jhernandez@cuentadealtocosto.org

Resumen

Antecedentes:

El cáncer de estómago se encuentra entre los más frecuentes y es una de las principales causas de mortalidad en los países de ingresos bajos y medianos. Evaluar su supervivencia es importante para orientar las políticas de salud basadas en la evidencia.

Objetivo:

Estimar la supervivencia del cáncer de estómago en Colombia (2014-2019) con datos del Sistema Nacional de Información del Cáncer (NCIS) y en Cali con datos del Registro Poblacional de Cáncer de Cali (RPCC) (1998-2017).

Métodos:

El NCIS estimó la supervivencia neta a tres años para 8,549 personas y el RPCC la calculó a 5 años para 6,776 personas registradas en sus bases de datos.

Resultados:

La supervivencia neta a tres años en Colombia fue del 36.8% (IC 95%: 35.5-38.1). La supervivencia neta fue mayor en personas con seguro especial (61.7%; IC 95%: 44.8-74.8) o tercer pagador (40.5%; IC 95%: 38.7-42.3) que el seguro estatal (30.7%; IC 95%: 28.7-32.8). También fue mayor en mujeres y personas diagnosticadas en etapas tempranas. El análisis multivariable mostró consistencia con la estimación de supervivencia con mayor riesgo de muerte en hombres, personas con seguro estatal y diagnosticados en estadios avanzados. En Cali, la supervivencia neta a 5 años se mantuvo estable en los hombres durante los últimos 20 años. En las mujeres aumentó 8.60 puntos porcentuales, equivalente a un aumento del 50% en comparación con el período 1998-2002. Para el período 2013-17 fue 19.1% (IC 95%: 16.2-22.2) en los hombres y 24.8% (IC 95%: 20.4-29.3) en las mujeres.

Conclusiones:

Las estimaciones de supervivencia del RPCC fueron más bajas que las obtenidas por el NCIS. Las diferencias en sus métodos y alcance pueden explicar la variabilidad. Sin embargo, nuestros hallazgos pueden ser complementarios para mejorar la planificación del control del cáncer en el país.

Remark

1) Why was this study conducted?

To estimate gastric cancer survival in the Colombian population notified to the National Cancer Information System (NCIS) that received health services within the framework of the national health system. To compare these results with those obtained by a population-based cancer registry.

2) What were the most relevant results of the study?

People with insurance paid by the government have lower gastric cancer survival than those affiliated with the third payer and the special insurance. The Colombian National Cancer Information System (NCIS) obtained gastric cancer survival estimates higher than those of the population-based cancer registry. Gastric cancer survival in Colombia has a gap of at least 40 percentage points compared to countries that perform population-based screening.

3) What do these results contribute?

The Colombian government can use survival indicators to monitor the gastric cancer control plan.

Introduction

Stomach cancer is among the most frequent and lethal types of cancer worldwide. By 2020, it was the fifth type in terms of incidence, and every year accounts for more than 1.1 million and 0.8 million new cases and deaths, respectively [1,2].

Stomach cancer is the leading cause of specific mortality in Colombia and Andean low-middle income countries in Latin America, where gastric cancer incidence rates are higher than those observed in high-income countries [3]. Although the stomach cancer burden of morbidity and mortality has steadily decreased in the last decades, its survival remains the lowest compared with other solid tumors such as breast, prostate, or cervical [4].

Survival is one of the most interesting indicators for cancer surveillance and control because it reflects the effectiveness of prevention and treatment. Associated factors with stomach cancer survival are diverse; and could be related to the individual, the disease itself, and the health system [5]. However, the key prognostic factor is staging at diagnosis, and it depends on a well-organized screening population program. Japan and Korea have significantly improved stomach cancer control through nationwide screening programs that can detect up to 70% of new cases in the early stages [6-8]. In Latin America, the screening coverage is poor, with low cost-effectiveness of the implemented programs [5,9-11]; and about 90% of people are diagnosed in advanced stages.

Colombia has a situation comparable to Latin America, lacking a nationwide stomach cancer screening program despite its epidemiologic and economic burden; as well as a high prevalence of *Helicobacter pylori* infection, which represents a major risk factor for stomach cancer [12]. According to the High-Cost Diseases Fund (CAC in Spanish), 73% of the new cases that received care within the framework of the national health system in 2019 were diagnosed in advanced stages [13].

The National Cancer Information System (NCIS) managed by the CAC collects and analyzes demographic, clinical, and administrative information on people with cancer in Colombia through the annual report of 134 variables. The NCIS methodology and scope have been published elsewhere [14].

The NCIS survival estimates are a metric of the effectiveness of cancer care providers and insurers in the Colombian health system that report cancer cases to the NCIS. On the other

hand, the Population-based cancer survival provides an indicator of the overall effectiveness of the health care system to deliver screening, early diagnosis, and evidenced-based treatment services and follow-up care to all individuals in the population. The survival estimates of both information systems are complementary, so they could serve as a mutual verification method [15,16].

Therefore, we aimed to estimate 3-year net survival at the national level in people treated within the framework of the national health system during the period 2015-2019, with data from NCIS managed by the CAC; and 5-year net survival in Cali from the Population-based Cancer Registry of Cali (RPCC in Spanish) during the period 1998-2017.

Materials and Methods

Setting

Colombia, a middle-income country, has a population of 50.6 million and a gross national income per capita of U.S. $6,510 [17]. In 1994, it was established the current health insurance system, which is considered public-private [18]. It is a universal and mandatory system that covers almost 96% of the total population. There are two insurance sources; the first is funded by the third payer, and groups the country's workforce; in the remaining cases, the state resources support the second, including the unemployed. The third payer and state insurance cover approximately 45% and 49% of the insured population. The remaining population is under private insurance, in addition to the third payer or government insurance (police, military forces, or government employees) [19].

Cali is the third-largest city in Colombia and the most densely populated in the country's southwest, with 20% of the Colombian population. According to the 2018 census, Cali had 2.2 million inhabitants, 53.2% of which were women, and 26.2% were self-reported as afro-descendants [20]. The average life expectancy at birth was 74.4 years [20]. Cali has more than 165 enabled oncology services in urban areas [21], but only five centers have integrative oncology services. More than 9.5 thousand new cancer cases were diagnosed in 2019, 55% of whom lived outside Cali.

Data sources

NCIS. The NCIS, administered by the CAC, performed survival analysis on real-world and nationwide data. The NCIS is a passive and non-public registry created by the Colombian Ministry of Health in 2014 [22]. Its goal is to collect and analyze demographic and clinical information on people who receive health services within the national health system through the annual report of 134 variables. The national health system insures 98% of the Colombian population, and health insurers and providers must report all cancer cases to the NCIS [19]. This information system can provide reliable information on real-life trends in access to health care for common types of cancer in Colombia, including identifying barriers to adequate access to treatment. To identify and protect the personal information of the participants, they have created unique identifiers. Data is updated for prevalent cases yearly, while new cancer cases are fully registered. A well-established data monitoring process guarantees information quality, which is carried out in two steps: a prior identification of mistakes in the reporting process through a systematized algorithm. Then, the reported information is audited and compared with clinical health records to ensure accuracy for all new cases. The NCIS methods and scope have been previously described [14]. In 2019, the proportion of data quality was up to 83%, and it has increased throughout the years, consolidating the NCIS as a reliable data source.

The Population-based Cancer Registry of Cali (RPCC). The RPCC has operated continuously since 1962. The official censuses carried out by the National Department of Statistics (DANE) in 1964, 1973, 1983, 1993, and 2005 provide information on the population of Cali [19,23].

The RPCC includes the new cases of stomach cancer throughout notification and active searching in primary data sources, including hospitals, clinics, pathology laboratories, and

cancer centers. General mortality by age, sex, and calendar year is periodically obtained from death certificates from the Secretary of Health in Cali. The RPCC integrates the data into the database following the international standards of good practice [24,25]. The RPCC is a certified member of the International Association of Cancer Registries and meets the international standards of quality recommended by the International Agency for Research on Cancer (IARC) [24,25]. Elsewhere is a complete review of history, goals, logistics, coverage, procedures, and methods for incidence, mortality, and survival estimations [21,26].

Patient selection

NCIS

Case definition. The NCIS included all the new cases of a primary stomach cancer in people aged ≥15 years and reported between January 2nd, 2014, and January 1st, 2019. Health providers confirmed the diagnosis on medical records through a data monitoring process. The International Classification of Diseases 10th edition (ICD-10) [27] defined the location (C160-C169) of the tumor. For net survival analysis, NCIS applied additional exclusion criteria. Cases with a time from diagnosis to death or last contact of unknown length or "0" years, as well as a follow-up time higher than the maximum (3 years), were excluded. Patients with tumors classified as *in-situ* were also excluded. Information regarding death was reported to the CAC by health insurers. In addition, the deaths were verified by external sources from the Ministry of Health and the National Registry of Civil Status.

RPCC

Case definition. Men and women aged 15-99 years old, residing in the urban area of Cali, with a diagnosis of primary malignant neoplasm of the stomach, codified as C16 according to the Classification of Diseases for Oncology 3rd edition (ICD-O-3)[28], no matter if it was confirmed or partially or fully treated; and registered in the RPCC from 1998 to 2017. The basis for the diagnosis can be microscopic (fluid cytology, bone marrow, histology of a primary tumor and autopsy); and non-microscopic (clinical, surgical, and imaging diagnosis). Cases that have come to the city for treatment or diagnosis are not considered as residing in Cali [15].

The RPCC updated the vital status and date of the last contact by crossing with external sources: the mortality database of the Secretary of Public Health in Cali, the registry of hospital discharges from medium and high complexity healthcare institutions, pathology reports, and insurance databases (public and private).

Full follow-up. People who die before or on the same follow-up closing date, o people who die after the follow-up closing date; or people who are alive and the date of the last contact is greater than the closing date of the follow-up.

Incomplete follow-up. People who are alive, and the date of the last contact is less than the closing date of the follow-up.

Cases with the following conditions were excluded from the analysis: i) cancer diagnosis only based on death certificates, showing the same date for both diagnosis and death, and ii) other causes: unknown age or sex and benign tumors. In the supplementary Table, S1 has summarized the quality indicators for cases.

Statistical Analyses

NCIS. We performed a descriptive analysis of demographic and clinical variables at baseline, including age at diagnosis, sex, health insurance, region of residence, and clinical stage. According to their distribution, continuous variables were reported as medians and interquartile ranges (IQR), while categorical data were summarized as absolute variables and proportions.

In all analyses, the dependent variable was the time between diagnosis and death for any cause or being censored. It was set to a maximum of 3 years. People who did not have the event or were lost to follow-up were censored. 3-year overall survival was estimated using the Kaplan-Meier method, while net survival was calculated through the Pohar-Perme estimator [29]. Life tables for all-cause mortality in the general Colombian population were built to estimate expected net survival. The period approach was used because the established follow-up was unavailable for all patients. We also analyzed overall survival and net survival by sex, health insurance, region of residence, and stage at diagnosis, comparing the curves with the log-rank test and the method developed by Pavlič and Perme (log-rank type test) [30], respectively. Net survival was age-standardized using a traditional direct method with an internal standard.

We also estimated a flexible parametric model with restricted cubic spline functions for modeling non-linear and time-dependent effects on the log excess hazard scale proposed by Royston-Parmar [30-33]. A generalized linear model using a Poisson assumption with smoothing splines was selected because it violated the proportional hazards principle. To determine the model's complexity and goodness of fit, the Akaike information criterion was evaluated [33].

The final model had 4 knots and 5 degrees of freedom. It was adjusted by age and stage at diagnosis, sex, health insurance, and region of residence, and the results are presented as hazard ratios (H.R.s) and their 95% confidence interval.

RPCC. The dependent variable was the time of follow-up between cancer diagnosis and the event of interest (death by any cause) or being censored. The maximum observation time until the occurrence of the event was five years. Censoring was defined as loss of follow-up and cases without the event at the end of the study period (December 31st, 2018).

The 20-year survival was estimated by combining the cohort analysis approach for the periods 1998-2002, 2003-2007, and 2008-2012, and the period analysis for the interval 2013-2017 due to the lack of complete five-year follow-up information for all subjects [34,35]. 5-year net survival was calculated by using the Pohar-Perme estimator [29]. Life tables for all-cause mortality in the general population in Cali were built from the number of deaths and population by age, sex and calendar year [35,36]. Survival estimations were age-standardized using the international cancer survival standard weights (group 1) [37].

Ethical considerations

NCIS. This study has no risk for participants. Information was collected and analyzed following international standards (The Declaration of Helsinki, The Belmont Report, and The International Guidelines prepared by the Council for International Organizations of Medical Sciences (CIOMS)), as well as national regulations (Resolution 8430 of 1993, stated by The Colombian Health Ministry) for conducting human research. Confidentiality was guaranteed throughout the information processing (reporting, managing, analysis, and publication). All records were anonymized before the analysis. Furthermore, access to data was restricted to the research team and the results only can be used for approved research or academic purposes.

RPCC. The RPCC follows the European Network of Cancer Registries (ENCR) guidelines [38]. The director of the RPCC is responsible for security data and confidentiality. Team members of the RPCC sign an agreement for maintaining data confidentiality and privacy of personal information. Access to the RPCC installations is restricted only for authorized personal. Confidential information is accessed by security passwords, closed files, and the destruction of supports with personal identification when they are no longer useful. Only the manager of the RPCC is authorized to perform the initial matching for detecting new cases and updating vital status and last contact information. Each case is identified with an internal I.D. assigned by the RPCC and all datasets are anonymized for statistical analysis.

This research study was approved by the institutional ethics committee of the Universidad del Valle as stated in the approval certificate number 001-020 dated January 2020.

Results

NCIS

Demographic and clinical characteristics at baseline. A total of 8,549 people reported from 2015 to 2019 met the inclusion criteria and were analyzed. Demographic and clinical characteristics of new cases of stomach cancer at baseline are shown in Table 1. Most cases occurred in men above 50 years, affiliated with the third payer insurance, living in the Central Region, and diagnosed in advanced stages.

Survival analysis. All participants contributed a total of 9,317 years, and 4,478 deaths were observed. The Median follow-up time was 0.8 years (min: 0.2 years, max: 3.0 years). 3-year net survival was 36.8% (95% CI: 35.5-38.1). Net survival at 1 and 2 years was 55.8% (95% CI: 54.7-56.9) and 41.2% (95% CI: 39.9-42.4), respectively.

Table 1. Age-standardized baseline demographic and clinical characteristics of people with stomach cancer within the Colombian health system, 2015-2019

Variable ‡	New cases (n=8,549)
Age at diagnosis (years)	65 (54-74)
Age groups	
15-19	6 (0.1)
20-24	36 (0.4)
25-29	95 (1.1)
30-34	184 (2.1)
35-39	264 (3.1)
40-44	374 (4.4)
45-49	619 (7.2)
50-54	868 (10.2)
55-59	969 (11.3)
60-64	1,061 (12.4)
65-69	1,111 (13.0)
70-74	1,044 (12.2)
75-79	930 (10.9)
80 and more	986 (11.6)
Sex	
Males	5,226 (61.1)
Females	3,323 (38.9)
Stage at diagnosis †	
Early	1,442 (16.9)
Advanced	4,709 (55.1)
Unknown	2,398 (28.0)
Health insurance	
Third payer	4,844 (56.6)
Paid by the state	3,459 (40.5)
Exception	79 (0.9)
Private	57 (0.7)
Uninsured	110 (1.3)
Geographical region of residence §	
Bogotá, D.C.	2,111 (24.7)
Caribbean	450 (5.3)
Central	2,852 (33.3)
Eastern	1,371 (16.0)
Pacific	1,649 (19.3)
Other provinces	116 (1.4)

‡ Values are absolute numbers (%). Age is reported as median (interquartile range).
† Stages IA, I.B., IIA and IIB were grouped as early. Advanced stage includes IIIA, IIIB, IIIC and IV.
§ Colombian provinces are grouped in six regions, according to their gross domestic product by the Department of National Statistics (DANE in Spanish) as follows: 1) Bogotá, D.C (country's capital); 2) Caribbean (Atlántico, Bolívar, Cesar, Córdoba, La Guajira, Magdalena and Sucre); 3) Central (Antioquia, Caldas, Caquetá, Huila, Quindío, Risaralda and Tolima); 4) Eastern (Boyacá, Cundinamarca, Meta, Norte de Santander and Santander); 5) Pacific (Cauca, Chocó, Nariño and Valle del Cauca); 6) Other provinces (Amazonas, Arauca, Casanare, Guainía, Guaviare, Putumayo, San Andrés, Vaupés and Vichada).

Figure 1. Colombia. Three-year net survival standardized by age according to health insurance in people diagnosed and treated with stomach cancer.

We also estimated net survival by sex, age, health insurance, stage and region of residence at diagnosis. Regarding health insurance (Figure 1), net survival was significantly higher in people affiliated to special insurance (61.7%; 95% CI: 44.8-74.8) or to the third payer (40.5%; 95% CI: 38.7-42.3) in those affiliated to state insurance (30.7%; 95% CI: 28.7-32.8) (log-rank type $p < 0.001$). Figure 2 shows that net survival was significantly higher in women (42.6%; 95% CI: 40.2-44.9) than men (34.8%; 95% CI: 33.1-36.5) (log-rank type $p < 0.001$).

On the other hand, net survival was significantly higher in people diagnosed at early stages (IA, IB, IIA, IIB) (58.1%; 95% CI: 54.5-61.5), compared with those at advanced stages (25.1%; 95% CI: 23.4-26.9) (log-rank type $p < 0.001$) (supplementary Figure S1). Net survival was also significantly higher in people aged <60 years (33.9%; 95% CI: 31.9-36.0), compared with those aged ≥60 years (38.4%; 95% CI: 36.7-40.1) (log-rank type $p < 0.001$).


Figure 2. Colombia. Three-year net survival standardized by age according to sex in people diagnosed and treated for stomach cancer.

Table 2. Multivariable-adjusted hazard ratios in people with stomach cancer treated within the Colombian health system

Variables §	Aged <60 years (n= 3,212)			Aged ≥60 years (n=5,335)		
	HR-adjusted	95% CI	p-value	HR-adjusted	95% CI	p-value
Sex						
Females (reference)	1.0	-	-	1.0	-	-
Males	1.1	0.9-1.2	0.209	1.2	1.1-1.3	<0.001
Health insurance						
Third payer (reference)	1.0	-	-	1.0	-	-
Paid by the state	1.1	0.9-1.2	0.335	1.3	1.2-1.4	<0.001
Exception	0.7	0.4-1.2	0.187	0.9	0.6-1.3	0.646
Special	0.5	0.2-0.9	0.036	0.7	0.4-1.3	0.220
Uninsured	1.0	0.7-1.5	0.915	0.9	0.6-1.4	0.660
Stage at diagnosis						
Unknown (reference)	1.0	-	-	1.0	-	-
Early	0.6	0.5-0.7	<0.001	0.6	0.5-0.7	<0.001
Advanced	1.5	1.4-1.7	<0.001	1.4	1.3-1.5	<0.001
Geographical region of residence						
Bogotá, D.C. (reference)	1.0	-	-	1.0	-	-
Caribbean	1.2	0.9-1.5	0.061	0.9	0.8-1.1	0.616
Central	0.9	0.8-1.1	0.742	0.8	0.7-0.9	<0.001
Eastern	0.9	0.8-1.1	0.388	0.9	0.8-1.1	0.747
Pacific	1.1	0.9-1.2	0.866	0.9	0.8-0.9	0.027
Other provinces	0.6	0.4-0.9	0.048	0.6	0.4-0.9	0.024

§ All variables were measured at diagnosis.
H.R.: hazard ratio, CI: confidence interval.

Supplementary Figure S2 shows net survival by region of residence at diagnosis. There were no statistically significant differences, except for people living in the Caribbean region (29.4%; 95% CI: 24.0-35.0), who had a significantly lower net survival than those in the Central region (38.5%; 95% CI: 36.2-40.8).

Flexible parametric model results. Overall, people under state insurance were at a higher risk of death those affiliated to the third payer (adjusted HR=1.2, 95% CI: 1.1-1.3; *p* <0.001). Otherwise, people with special insurance had a significantly lower risk (adjusted HR=0.6, 95% CI: 0.4-0.9; *p*= 0.022). Regarding sex, men had a significantly higher risk of death than women (adjusted HR=1.2, 95% CI: 1.1-1.2; *p* <0.001). Furthermore, people diagnosed at early stages had a lower risk of death than those with unknown staging (adjusted HR=0.6, 95% CI: 0.5-0.7; *p* <0.001). The age-stratified model showed a higher risk in men aged ≥60 years. Furthermore, older people with state insurance risk was also higher than younger people. The effect of early detection remained the same despite age (Table 2).

RPCC

Six thousand seven hundred seventy-six people diagnosed with stomach cancer, living in Cali, and registered in the RPCC database between 1998 and 2019, aged between 15 and 99 years, were included in survival analysis (42.4% were women). Otherwise, 687 cases (9.2%) were excluded (25,26). During the period 2013-2017, 83.3% of cases were morphologically verified, and 2.7% had a death certificate as the only evidence for cancer diagnosis.

Table 3 shows 1, 3, and 5-year net survival for both sexes of people with stomach cancer between 1998 and 2019. In the last decade (2008-2017), 5-year net survival was close to 21% being, significantly higher than the previous decade (1998-2007). Furthermore, in the last quinquennium, it improved by 4.7 percentage points that representing an increase of 25% compared with the first quinquennium (21.3% (95 CI%: 19.2-23.6) vs. 16.6% (95% CI: 19.2-23.6)).

5-year net survival by sex is described in Table 4. In men, it remained stable during the last 20 years; while in women, it significantly improved in the last decade, showing an increase of 50% (8.6 percentage points) in the previous quinquennium compared with the first one (24.8% (95% CI: 20.4-29.3) vs. 16.2% (95% CI: 13.1-19.7)).

Table 3. Cali, Colombia. Age-standardized net survival at 1, 3 and 5 years in adults (15-99 years) diagnosed with stomach tumors, by calendar period (both genders).

Period of diagnosis	Net Survival §					
	1 year	95% CI	3 years	95% CI	5 years	95% CI
1998-2002	32.1	29.8 - 34.3	18.8	16.7 -21.1	16.6	14.5 -18.9
2003-2007	35.1	33.0 - 37.1	21.0	19.1 - 23.1	18.7	16.7 -20.9
2008-2012	39.4	37.2 - 41.5	22.7	20.7 - 24.8	21.0	18.9 - 23.2
2013-2017	43.8	41.4 - 46.0	23.8	21.7 - 25.9	21.3	19.2 - 23.6

§ Values are percentages.
CI: confidence interval.

Table 4. Cali, Colombia. Age-standardized net survival at 5 years in adults (15-99 years) diagnosed with stomach tumors, by sex and calendar period.

Period of diagnois	Male		Female		Both	
	NS§	95% CI	NS §	95% CI	NS§	95% CI
1998-2002	17.2	14.3 - 20.4	16.2	13.1 -19.7	16.6	14.5 -18.9
2003-2007	18.5	15.8 - 21.5	19.2	16.2 -22.4	18.7	16.7 -20.9
2008-2012	19.1	16.4 - 21.9	24.0	20.4 -27.8	21.0	18.9 - 23.2
2013-2017	19.1	16.2 - 22.2	24.8	20.4 -29.3	21.3	19.2 - 23.6

§ Values are percentages.
NS: net survival; CI: confidence interval.

Supplementary Table S1shows that about 63% of people diagnosed with stomach cancer died during the first year of follow-up.

Discussion

The NCIS provides nationwide stomach cancer data; this survival analysis was performed with Observational Routinely collected health Data (RECORD). In addition, the Cali population-based Cancer Registry, one of the oldest in Latin America, compared these survival estimates at the national level with those calculated by its team for the city of Cali.

Population-based cancer survival reflects the overall effectiveness of the health system for cancer control. It measures the mean survival achieved by all patients with stomach cancer despite their demographic and clinical conditions. Survival is the primary goal in the care of patients with stomach cancer. Early detection of stomach cancer and radical surgery associated with adjuvant treatments are the driving force behind stomach cancer control [39].

Stomach cancer is a multifactorial disease mainly related to *Helicobacter pylori* gastritis, which usually begins early. Environmental, infectious and host-related factors may interact to develop the disease. During the last half-century, stomach cancer incidence and mortality rates have significantly decreased worldwide. It is associated with the lower use of salt in processed food and the greater availability of fresh fruits and vegetables. In many countries, tobacco use and the prevalence of *H. pylori* infection have also decreased [40,41].

Unfortunately, advances in the treatment of stomach cancer are insufficient, there is no vaccine development against *H. pylori*, and early detection programs in Latin America have not been successful due to a lack of continuity and low-cost effectiveness. Chemoprevention remains an option for stomach cancer control as a primary prevention strategy to eradicate *H. pylori* infection [9,10].

Regarding our analysis, the CAC gathers a large volume of RECORD data by an interconnection platform that allows the flow of cancer data in real-time between health insurers and providers [42]. On the other hand, the RPCC was established in 1962; it is a population-based cancer registry that provides continuous information on new cases of all types of cancer in permanent residents of Cali through active search and notification[21,26]. For stomach cancer survival analysis, these two information systems, CAC and RPCC, have comparable variables for the person, tumor, vital status, and date of the last contact. Unfortunately, there is a limitation to obtaining information about staging.

The 3-year net survival was 36.8% (95% CI: 35.5-38.1), according to the NCIS. In the flexible parametric model, we found that people with insurance paid by the state had a significantly higher risk of death than those affiliated to the third payer and the special insurance. The mortality risk was also significantly higher in men than women; and in people diagnosed at advanced stages. When analyzing data from the RPCC, the 5-year net survival during the period 2013-2017 was 21.3%. In addition, we observed it was almost stable in men; while in women, it significantly improved in the last decade and, in the previous quinquennium, it showed an increase of 50% compared with the first one.

Stomach cancer survival from the RPCC was higher than observed in other Latin American countries such as Ecuador and Chile (19.1% and 16.7%, respectively) while were lower than estimated in Costa Rica (40.0%) during the period 2010-2014 [22] (Supplementary Table S2). The above suggests that stomach cancer continues to have a high social burden in Cali and Colombia, being the major cause of cancer deaths [26,43].

In most countries, advances in surgical and multimodality treatments and post-operative care have only modestly improved survival and prognosis. South Korea and Japan have well-established national stomach cancer prevention and screening programs [2,44] with 5-year net survival of 69% and 60% (Supplementary Table S2), respectively, with an average increase between 10% and 20% in the last 20 years according to CONCORD-3 [35]. In those countries, strategies have been focused on eradicating *H. pylori* and the early detection of cancer by population-based endoscopic screening programs.

CONCORD-3 results also highlighted that survival increased up to 5% in five European countries (Denmark, Lithuania, and the United Kingdom in North Europe, Poland in Eastern Europe and Austria in western Europe), with 5-year net survival ranging from 20% to 27%. In the United States and Austria, survival estimations ranged from 30% to 35% during the period 2010-2014 [35].

When comparing survival in Japan or Korea with the estimations reported in the United States, the overall difference is due to earlier diagnosis, fewer proximal and gastroesophageal junction lesions, and histologic or genetic variations in Asian countries [45,46]. Self-selection bias and lead-time bias could overestimate the survival gap between countries. Healthy or health-conscious individuals may overrepresent participants in screening programs, and ever-screened patients may seem to be surviving longer because they are diagnosed earlier, not screening-test effect. It could lead to an overestimation of the effectiveness of the screening program. Western countries such as Colombia have no population-based screening programs for stomach cancer [47].

Results from both the NCIS and the RPCC are consistent regarding better survival in women than men. In contrast, in Japan, women show a small but consistently lower survival associated with more advanced stages among women. It suggests a gender inequity in screening, medical examinations, or treatment for stomach cancer in Japan [48]. Our findings show that gender inequity in Colombia goes in the opposite direction.

One of the most important findings from the NCIS analysis was the statistically significant differences in the risk of death by health insurance, with better outcomes in people affiliated with the third payer or special insurance than those insured by the state. Our results are consistent with a study performed with data from a population-based registry in Manizales, Colombia. People affiliated with the third payer had about 30% lower risk of dying than people with state insurance [49]. In both cases, insurance could be a proxy of access and health care quality. It would also represent the distribution of exogenous sociodemographic factors related to risk awareness and a timely diagnosis and treatment [50]. Despite the increase in coverage from 2010, there is differential access to health care according to the insurance system, and inequities in cancer diagnosis and treatment persist even between types of insurance [49].

Finally, it is worth mentioning that our results are valuable for improving cancer planning and strengthening national information systems on cancer and population registries. Furthermore, results from both approaches allow identifying gaps in the reporting process of cancer cases that receive care within the national health system. Regardless of differences in their methodology and scope, the NCIS and RPCC information may be complementary to identify cancer burden in terms of its frequency, distribution at demographic and insurance levels, as well as barriers for adequate access to health care and outcomes of cancer management performed by insurers and providers such as survival.

Prevention will always be preferable to cure, especially for gastric cancer with high lethality. Unfortunately, there is no vaccine development against *H. pylori*, and early detection programs in Latin America have not been successful. Therefore, chemoprevention remains an option for stomach cancer control as a primary prevention strategy to eradicate *H. pylori* infection.

However, cancer treatment costs are increasing and creating financial hardship in providing high-quality cancer care equally to all citizens. The evidence from this research suggests that there is inequality in gastric cancer care in the current Colombian health system. People with insurance paid by the government have lower survival than those affiliated with the third payer and the special insurance. Decision-makers in the Colombian government, insurance companies, and hospitals that provide cancer care in the Colombian health system must introduce policy changes to reduce existing gaps. It is unacceptable that there is political tolerance of inequality in access to affordable cancer care [16].

Strengths and limitations

Our study's main strength was exploring stomach cancer survival from two different but complementary data sources. Data from the NCIS provides a real-world approach from an insurance perspective at the national level, while the RPCC is population-based. Also, data from the NCIS was fully validated by a well-established and systematic data monitoring process. Regarding deaths, the official source of the Ministry of Health confirms that they are exhaustively validated [14].

On the other hand, population-based survival estimates by the RPCC reflect all patients with stomach cancer in Cali, regardless of socioeconomic status and disease characteristics. In addition, the RPCC follows the CONCORD-3 guidelines for the standardization, cleaning, and construction of quality indicators. This process facilitates a specific exclusion of cases from the study and allows a uniform coding format for the mandatory variables [16,35].

There is a limitation regarding the comparability of survival estimates obtained by the RPCC and the CAC due to their different definition of the stomach cancer case [21,51]. The RPCC includes invasive stomach cancer cases, regardless of whether they have been confirmed or partially, or fully treated. The basis of the diagnosis can be both morphological; as non-morphological. For the 2013-2017 period, 83.3% of stomach cancer cases had morphological verification. In 14%, the diagnosis was clinical, and in 2.7%, the cancer cases were registered from the death certificate only [52].

In contrast, Colombian health insurers notify the CAC of stomach cancer cases with morphological or clinical confirmation treated in the framework of the national health system. Although notification of stomach cancer cases to the CAC is mandatory, it does not guarantee the completeness and could limit the comparability of our findings [14,51].

Due to the above, the NCIS information could underestimate cancer incidence rates and overestimate survival compared to those obtained by the RPCC. In addition, the quality of notification of cancer cases is related to the organization of cancer services, which influences the clinical outcomes of cancer.

The RPCC does not have information on tumor stages in patients with stomach cancer. The RPCC passively follows up to obtain the vital status of the patient and the date of the last

contact. The RPCC periodically updates the vital status with the Secretary of Health in Cali, but the linkage with the national databases is insufficient and depends on death certificates that have inherent inaccuracies and missing data. Furthermore, Cali does not have a census of the migratory flows of the population and lacks life tables by socioeconomic stratum and by the state of insurance to the national health system.

Final comments

The RPCC and CAC regularly conduct cancer situational analyses and are essential to monitor and evaluate national and regional progress in stomach cancer surveillance and control. Collaboration between reporting systems and cancer registries enables these complementary systems to verify survival estimates to identify gaps, implement standards, and develop improvement plans to ensure data quality.

The standardization of the data allows regional and international comparisons and facilitates decision-making. It is a priority to unify the case definition and for the CAC to work with the cancer registries to complement the incidence and survival information and achieve the link with the national databases to improve the passive follow-up process.

References

1. Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. C.A. Cancer J Clin. 2018;68(6):394-424. doi: 10.3322/caac.21492.

2. Rawla P, Barsouk A. Epidemiology of gastric cancer: Global trends. risk factors and prevention. Prz Gastroenterol. 2019;14(1):26-38. doi: 10.5114/pg.2018.80001.

3. International Agency for Research on Cancer. Global Cancer Observatory. Estimated deaths in 2018. Colombia; 2018. Available from: https://gco.iarc.fr/today/data/factsheets/populations/170-colombia-fact-sheets.pdf

4. Yang D, Hendifar A, Lenz C, Togawa K, Lenz F, Lurje G, et al. Survival of metastatic gastric cancer: Significance of age. sex and race/ethnicity. J Gastrointest Oncol. 2011;2(2):77-84. doi: 10.3978/j.issn.2078-6891.2010.025.

5. Llorens P. Gastric cancer mass survey in Chile. Semin Surg Oncol. 1991;7(6):339-43. doi: 10.1002/ssu.2980070604.

6. Asaka M, Mabe K, Strategies for eliminating death from gastric cancer in Japan. Proc Japan Acad Ser B Phys Biol Sci. 2014;90(7):251-8. doi: 10.2183/pjab.90.251.

7. Yuan Y. A survey and evaluation of population-based screening for gastric cancer. Cancer Biol Med. 2013;10(2):72-80. doi: 10.7497/j.issn.2095-3941.2013.02.002.

8. Hamashima C, Kato K, Miyashiro I, Nishida H, Takaku R, Terasawa T, et al. Update version of the Japanese guidelines for gastric cancer screening. Jpn J Clin Oncol. 2018;48(7):673-83. doi: 10.1093/jjco/hyy077.

9. Pisani P, Oliver WE, Parkin DM, Alvarez N, Vivas J. Case-control study of gastric cancer screening in Venezuela. Br J Cancer. 1994;69(6):1102-5. doi: 10.1038/bjc.1994.216.

10. Rosero-Bixby L, Sierra R. X-ray screening seems to reduce gastric cancer mortality by half in a community-controlled trial in Costa Rica. Br J Cancer. 2007;97(7):837-43. doi: 10.1038/sj.bjc.6603729.

11. Goss PE, Lee BL, Badovinac-Crnjevic T, Strasser-Weippl K, Chavarri-Guerra Y, Louis JS, et al. Planning cancer control in Latin America and the Caribbean. Lancet Oncol. 2013;14(5):391-436. doi: 10.1016/S1470-2045(13)70048-2.

12. Flores-Luna LF, Bravo MM, Kasamatsu E, Lazcano EC, Martinez T, Torres J, et al. Risk factors for gastric precancerous and cancers lesions in Latin American counties with difference gastric cancer risk. Cancer Epidemiol. 2021;64:1-21. doi: 10.1016/j.canep.2019.101630.

13. Fondo Colombiano de Enfermedades de Alto Costo. Situación del cáncer en la población adulta atendida en el SGSS de Colombia 2020. Bogotá D.C.; 2021.

14. Hernández VJA, Ramírez BPX, Valbuena-Garcia AM, Acuña-Merchán LA, González-Diaz JA, Lopes G. National cancer information system within the framework of health insurance in Colombia: a real-world data approach to evaluate access to cancer care. JCO Glob Oncol. 2021; (7): 1329-40. doi: 10.1200/GO.21.00155.

15. Weir HK, Stewart SL, Claudia A, White MC, Thomas CC, White A, et al. Population-Based Cancer Survival (2001 to 2009) in the United States: Findings From the CONCORD-2 Study. 2018;123(Suppl 24):4963-8. doi: 10.1002/cncr.31028.

16. Coleman MP. Cancer survival: Global surveillance will stimulate health policy and improve equity. Lancet. 2014;383(9916):564-73. doi: 10.1016/S0140-6736(13)62225-4

17. The World Bank. Gross National Income (GNI) per capita in Colombia. 2019. Available from: https://data.worldbank.org/indicator/NY.GNP.PCAP.CD?locations=CO

18. The World Bank. Gross National Income (GNI) per capita in Colombia. 2019. Available from: https://data.worldbank.org/indicator/NY.GNP.PCAP.CD?locations=CO

19. Ministerio de Salud y Protección Social. Cifras de aseguramiento en salud. Ministerio de Salud y Protección Social ; 2020. Available from: https://www.minsalud.gov.co/proteccionsocial/Paginas/cifras-aseguramiento-salud.aspx

20. Departamento Administrativo Nacional de Estadísticas DANE. Censo Nacional de Población y Vivienda (CNPV) 2018. Estimaciones de la población ajustada por cobertura censal; 2018. Available from: https://www.dane.gov.co/index.php/estadisticas-por-tema/demografia-y-poblacion/censo-nacional-de-poblacion-y-vivenda-2018

21. García LS, Bravo LE, Collazos P, Ramírez O, Carrascal E, Nuñez M, et al. Cali cancer registry methods. Colomb Med (Cali). 2018;49(1):109-20. doi: 10.25100/cm.v49i1.3853

22. Ministerio de Salud y Protección Social. Resolución 4496 por el cual se organiza el Sistema nacional de información en cáncer y se crea el observatorio nacional de cancer; Bogotá; 2012.

23. Departamento Administrativo Nacional de Estadísticas DANE. Estimaciones y proyecciones de población periodo 1985-2020. Bogotá D.C.; 2010.

24. Bray F, Parkin DM. Evaluation of data quality in the cancer registry: Principles and methods. Part I: Comparability, validity and timeliness. Eur J Cancer. 2009;45(5):747-55. Doi: 10.1016/j.ejca.2008.11.032.

25. Parkin DM, Bray F. Evaluation of data quality in the cancer registry: Principles and methods Part II Completeness. Eur J Cancer. 2009;45(5):756-64. Doi: 10.1016/j.ejca.2008.11.033

26. Bravo LE, García LS, Collazos P, Carrascal E, Ramírez O, Collazos T, et al. Reliable information for cancer control in Cali Colombia. Colomb Med (Cali). 2018;49(1):23-34. 10.25100/cm.v49i1.3689.

27. World Health Organization. International Statistical Clasiffication of Diseases and Related Problems. 2nd ed. Geneva. Switzerland; 2003.

28. Fritz A. International Classification of Diseases for Oncology: ICD-O. 3rd ed. World Health Organization. Geneva. Switzerland; 2000.

29. Perme MP, Stare J. Estève J. On Estimation in Relative Survival. Biometrics. 2012;68(1):113-20. doi: 10.1111/j.1541-0420.2011.01640.x.

30. Pavlic K, Perme MP. On comparison of net survival curves. BMC Med Res Methodol. 2017;17(1):1-12. doi: 10.1186/s12874-017-0351-3.

31. Lambert PC, Royston P, Dickman PW, Rutherford MJ, Maringe C, Pohar PM, et al. Strcs: A command for fitting flexible parametric survival models on the log-hazard scale. Stata J. 2016;15(1):1-13. Doi: .org/10.1186/s12874-015-0057-3

32. Maringe C, Pohar PM, Stare J, Rachet B. Explained variation of excess hazard models. Stat Med. 2018;37(14):2284-300. doi: 10.1002/sim.7645.

33. Lambert PC, Royston P. Further development of flexible parametric models for survival analysis. Stata J. 2009;9(2):265-90. Doi: 10.1177/1536867X09009002

34. Brenner H, Gefeller O. Deriving more up-to-date estimates of long-term patient survival. J Clin Epidemiol. 1997;50(2):211-6. doi: 10.1016/s0895-4356(97)00280-1.

35. Allemani C, Matsuda T, Di Carlo V, Harewood R, Matz M, Niksic M. Global surveillance of trends in cancer survival 2000-14 (CONCORD-3): analysis of individual records for 37 513 025 patients diagnosed with one of 18 cancers from 322 population-based registries in 71 countries. Lancet. 2018;391(10125):1023-75. doi: 10.1016/S0140-6736(17)33326-3.

36. Spika D, Bannon F, Bonaventure A, Woods LM, Harewood R, Carreira H, et al. Life tables for global surveillance of cancer survival (the CONCORD programme): Data sources and methods. BMC Cancer. 2017;17(1):1-14. doi: 10.1186/s12885-017-3117-8.

37. Corazziari I, Quinn M, Capocaccia R. Standard cancer patient population for age standardising survival ratios. Eur J Cancer. 2004;40(15):2307-16. doi: 10.1016/j.ejca.2004.07.002.

38. Tyczynski J, Démaret E, Parkin D. Standards and guidelines for cancer registration in Europe: The ENCR recommendations. In: International Agency for Research on Cancer. editor. The ENCR recommendations. 1st ed. Lyon. France; 2003.

39. Sitarz R, Skierucha M, Mielko J, Offerhaus GJA, Maciejewski R, et al. Gastric cancer: epidemiology, prevention, classification, and treatment. Cancer Manag Res. 2018; 10: 239-248. doi: 10.2147/CMAR.S149619.

40. Bray F, Jemal A, Grey N, Ferlay J, Forman D. Global cancer transitions according to the Human Development Index (2008-2030): A population-based study. Lancet Oncol. 2012;13(8):790-801. Doi: 10.1016/S1470-2045(12)70211-5

41. Verdecchia A, Mariotto A, Gatta G, Bustamante-Teixeira MT, Ajiki W. Comparison of stomach cancer incidence and survival in four continents. Eur J Cancer. 2003;39(11):1603-9. doi: 10.1016/s0959-8049(03)00360-5.

42. Ministerio de Salud y Protección Social. Resolución 247 Por el cual se establece el reporte para el registro de pacientes con cáncer. Ministerio de Salud y Protección Social; 2014.

43. Pardo C, Cendales R. Cancer incidence estimates and mortality for the top five cancer in Colombia 2007-2011. Colomb Med (Cali). 2018;49(1):16-22. doi: 10.25100/cm.v49i1.3596.

44. Uno Y. Prevention of gastric cancer by Helicobacter pylori eradication: A review from Japan. Cancer Med. 2019;8(8):3992-4000. doi: 10.1002/cam4.2277.

45. Strong V, Song K, Park C. Comparison of gastric cancer survival following R0 resection in the United States and Korea using an internationally validated nomogram. Ann Surg. 2010;251:640-6. doi: 10.1097/SLA.0b013e3181d3d29b.

46. Noguchi Y, Yoshikawa T, Tsuburaya A. Is gastric carcinoma different between Japan and the United States? Cancer. 2000;89:2237-46.

47. Murillo R. Control del cáncer de cuello uterino en Colombia: triunfos y desafíos de la tamización basada en la citología cérvico-uterina. Biomédica. 2008; 28(4): 1-4.

48. Sato N, Ito Y, Ioka A, Tanaka M, Tsukuma H. Gender differences in stomach cancer survival in Osaka. Japan: Analyses using relative survival model. Jpn J Clin Oncol. 2009;39(10):690-4. doi: 10.1093/jjco/hyp084.

49. Arias-Ortiz NE, de Vries E. Health inequities and cancer survival in Manizales. Colombia: A population-based study. Colomb Med (Cali). 2018;49(1):63-72. doi: 10.25100/cm.v49i1.3629.

50. Woods L, Rachet P, Coleman M. Origins of socio-economic inequalities in cancer survival: a review. Ann Oncol. 2006;17(1):15-9. doi: 10.1093/annonc/mdj007.

51. Ramirez-Barbosa P, Merchan LA. Cancer risk management in Colombia. 2016. Colomb Med (Cali). 2018;49(1):128-134. doi: 10.25100/cm.v49i1.3882.

52. Bravo LE, García LS, Collazos P, Carrasca E, Grillo E, Millán E. Descriptive epidemiology of cancer in Cali. 60 years of experience. Colomb Med (Cali). 2022;53(1): e2005050. Doi:10.25100/cm.v53i1.5050

Supplementary material.

Table S1. Quality indicators in people diagnosed with stomach cancer, both sexes, Cali, Colombia (1998-2017)

Year	Patients (n)	ASR (W)	Age <15 (n)	MV (%)	DCO (%)	Excluded No.	Excluded %	Excluded DCO (n)	Excluded Others (n)	Included No.	Included %	Dead (n)	Complete F-U (%)	1 year	LFU 0-1y	3 years	LFU 1-3y	5 years	LFU 3-5y	Median F-U (months)
1998	322	21.99	0	79.2	9.6	42	13.0	31	11	280	87.0	229	82.1	0.35	13.9	0.15	0.0	0.11	0.0	2.7
1999	316	20.32	1	72.5	11.7	54	17.1	37	17	262	82.9	200	77.1	0.39	9.9	0.27	1.5	0.22	0.4	3.5
2000	339	21.14	0	70.8	13.9	57	16.8	46	11	282	83.2	240	85.1	0.31	8.2	0.15	0.4	0.12	0.0	2.6
2001	341	20.80	0	72.4	13.8	51	15.0	47	4	290	85.0	233	81.0	0.38	8.6	0.22	0.0	0.20	0.3	4.4
2002	352	20.43	0	73.3	13.9	73	20.7	43	30	279	79.3	228	82.1	0.33	8.6	0.21	0.7	0.18	0.0	2.9
2003	349	19.11	0	75.9	10.6	45	12.9	37	8	304	87.1	244	80.6	0.42	9.2	0.25	0.3	0.21	0.3	4.9
2004	392	20.16	0	79.6	8.9	45	11.5	35	10	347	88.5	288	83.3	0.38	6.6	0.23	0.0	0.20	0.6	5.1
2005	409	20.48	0	78.7	10.0	57	13.9	41	16	352	86.1	302	85.8	0.34	6.8	0.19	0.3	0.14	0.0	3.8
2006	398	18.63	0	82.7	5.3	30	7.5	20	10	368	92.5	319	87.0	0.32	4.1	0.19	0.0	0.17	0.0	3.7
2007	381	17.42	0	82.7	3.9	20	5.2	15	5	361	94.8	314	87.3	0.40	1.7	0.20	0.0	0.17	0.0	5.4
2008	346	15.27	0	84.1	4.0	17	4.9	10	7	329	95.1	283	86.3	0.33	2.1	0.19	0.0	0.16	0.0	4.1
2009	344	14.54	0	83.7	4.1	17	4.9	11	6	327	95.1	271	83.2	0.37	2.4	0.23	0.0	0.20	0.0	5.6
2010	376	15.37	1	85.4	2.9	13	3.5	10	3	363	96.5	304	84.8	0.40	0.6	0.21	0.0	0.18	0.0	6.6
2011	379	14.78	0	85.2	2.9	11	2.9	10	1	368	97.1	308	84.0	0.42	0.5	0.23	0.3	0.21	0.3	7.2
2012	382	14.66	0	82.7	1.3	9	2.4	5	4	373	97.6	309	87.7	0.39	1.6	0.20	0.0	0.18	0.0	6.0
2013	399	14.77	0	80.2	2.3	24	6.0	6	18	375	94.0	318	97.1	0.37	2.7	0.18	0.0	0.14	0.3	4.5
2014	424	15.02	0	75.2	5.2	35	8.3	21	14	389	91.7	325	97.7	0.36	2.1	0.20	0.0	-	-	5.2
2015	385	13.28	0	70.9	6.0	35	9.1	21	14	350	90.9	281	95.1	0.35	3.4	0.19	1.4	-	-	2.8
2016	395	13.34	0	75.4	6.1	42	10.6	18	24	353	89.4	286	95.8	0.37	4.0	-	-	-	-	4.8
2017	434	14.20	1	84.6	0.9	10	2.3	4	6	424	97.7	323	98.3	0.36	0.9	-	-	-	-	5.4
Total	**7,463**	**16.66**	**3**	**78.9**	**6.7**	**687**	**9.2**	**468**	**219**	**6,776**	**90.8**	**5,605**	**87.6**	**0.37**	**4.5**	**0.20**	**0.3**	**0.16**	**0.1**	**4.5**

ASR: age-standardized rate; DCO: death certificate only; F-U: follow-up; MV: microscopically verified.

Table S2. Age-standardized five-year net survival in adults (15-99 years) diagnosed with stomach tumors, by country and calendar period of diagnosis (2000-2004, 2005-2009, 2010-2014)

| Country		Period of diagnosis					
		2000-2004		2005-2009		2010-2014	
		N.S. (%)	95% CI	NS (%)	95% CI	NS (%)	95% CI
America (Central and South)							
Cali. Colombia		18.4	16.0 - 20.9	18.1	15.9 - 20.2	17.1§	14.7 - 19.4
Colombia	(4 registries)	18.4	16.0 - 20.9	17.7	16.2 - 19.3	17.1§	15.4 - 18.8
Ecuador	(5 registries)	17.8	12.3 - 23.3	17.4	12.0 - 22.7	19.1	13.1 - 25.1
Chile	(4 registries)	14.5	11.7 - 17.4	16.3	14.7 - 18.0	16.7	14.2 - 19.3
Costa Rica *		48.4	45.5 - 51.2	38.4	36.3 - 40.5	40.6	38.5 - 42.7
America (North)							
United States	(48 registries)	26.2	25.8 - 26.5	30.1	29.7 - 30.4	33.1	32.7 - 33.4
Asia							
Japan	(16 registries)	50.5	50.0 - 50.9	57.6	57.3 - 57.9	60.3	59.9 - 60.7
Korea*		48.6	48.2 - 48.9	61.1	60.8 - 61.5	68.9	68.6 - 69.2
Northern Europe							
Denmark *		14.7	13.2 - 16.3	15.4	13.9 - 16.9	19.9	18.1 - 21.6
Lithuania*		22.0	20.7 - 23.3	24.9	23.4 - 26.4	27.0	24.9 - 29.0
United Kingdom*	(4 registries)	16.2	15.7 - 16.6	19.2	18.7 - 19.7	20.7	20.1 - 21.2
Eastern Europe							
Poland *	(16 registries)	15.9	15.2 - 16.5	19.9	19.3 - 20.4	20.9	20.3 - 21.4
Western Europe							
Austria *		30.0	28.7 - 31.3	34.2	32.9 - 35.6	35.4	34.0 - 36.9
Netherlands *		19.7	18.8 - 20.6	22.9	22.0 - 23.9	25.0	24.0 - 26.0

N.S. (%): Age-standardized five-year net survival
§: Survival estimate considered less reliable because 15% or more of patients were (a) lost to follow-up or censored alive within five years of diagnosis or. if diagnosed in 2010 or later. before December 31st 2014; or (b) registered only from a death certificate or at autopsy; or (c) registered with incomplete dates. i.e.. unknown year of birth. unknown month and/or year of diagnosis. or unknown year of last vital status.
* Data with 100% coverage of the national population.
Source: CONCORD-3. Lancet 2018;391 (10125).

Figure S1

Age-standardized net survival at 3 years in people diagnosed with stomach cancer in Colombia, by stage at diagnosis. Comparison of net survival by stage at diagnosis in people with stomach cancer diagnosed and treated in the framework of the Colombian health system. Stages IA and IB were grouped as early. Advanced stages include IIA, IIB, IIIA, IIIB, IIIC, y IV.

Figure S2.

Age-standardized net survival at 3 years in people diagnosed with stomach cancer in Colombia, by region of residence. Comparison of net survival by region of residence in people with stomach cancer diagnosed and treated in the framework of the Colombian health system. Colombian provinces are grouped in six regions according to their gross domestic product by the Department of National Statistics (DANE in Spanish) as follows: 1) Bogotá. D.C (' 'country's capital); 2) Caribbean (Atlántico. Bolívar. Cesar. Córdoba. La Guajira. Magdalena and Sucre); 3) Central (Antioquia. Caldas. Caquetá. Huila. Quindío. Risaralda and Tolima); 4) Eastern (Boyacá. Cundinamarca. Meta. Norte de Santander and Santander); 5) Pacific (Cauca. Chocó. Nariño and Valle del Cauca); 6) Other provinces (Amazonas. Arauca. Casanare. Guainía. Guaviare. Putumayo. San Andrés. Vaupés and Vichada).